Oxford Biomedica
From Kidney Cancer Resource
Contents |
Overview
Their web site can be seen with a Click Here
Oxford BioMedica plc.,
Chief executive Prof Alan Kingsman.
Medawar Centre
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA
United Kingdom
Telephone: +44 (0) 1865 783 000
For general enquiries, contact: [email protected]
Details
Clinical Trials / Overview
Oxford BioMedica has two products in clinical trials for the treatment of cancer, TroVax® and MetXia®. The company is currently recruiting for the trials as detailed below.
TroVax is being developed by Oxford Biomedica in collaboration with Sanofi-Aventis.
Renal Cell Carcinoma Advanced or metastatic renal cell carcinoma
Open label trial of TroVax in combination with interferon-alpha The Methodist Hospital in Houston, Texas, USA. (Principal Investigator: Dr Amato, contact Joan Hernandez-McClain , Coordinator, +1 713-441-7943, email [email protected])
Renal Cell Carcinoma Advanced or metastatic renal cell carcinoma
Open label trial of TroVax in combination with Interferon-alpha The Christie Hospital, Manchester, UK. (Principal Investigator: Professor R Hawkins, contact Catriona Parker, Coordinator, +44 (0)161 446 8400, email [email protected]) This study is fully recruited
Renal Cell Carcinoma Advanced or metastatic renal cell carcinoma
Open label trial of TroVax in combination with low dose Interleukin-2 The Methodist Hospital in Houston, Texas, USA (Principal Investigator: Dr Amato, contact Joan Hernandez-McClain , Coordinator, +1 713-441-7943, email [email protected]) This study is fully recruited
Renal Cell Carcinoma Metastatic renal cell carcinoma
Open label trial of TroVax in combination with high dose Interleukin-2 The Presbyterian Hospital/Columbia University Medical Center in New York, USA (Principal Investigator: Howard L. Kaufman MD, contact Gail DeRaffele RN, Clinical Coordinator, +1 212 342 0232, [email protected])
Phase III Trials
Renal Cell Carcinoma Advanced or metastatic renal cell carcinoma
TRIST: TroVax Renal Immunotherapy Survival Trial Randomised trial of TroVax or placebo in combination with standard therapy
Standard therapy is Interleukin-2, Interferon-alpha or sunitinib
Centres in USA, EU, Eastern Europe and Russia (contact trist@oxfordbiomedica.co.uk) For more information see Click Here
The following info. is from an article 13-Sep-2007 in Oxford Mail (KC) :
GENE therapy company Oxford Biomedica is to receive a £6m payment after hitting a research milestone.
Pharmaceutical company Sanofi-aventis is making the payment after 350 kidney cancer patients enrolled in the Phase III trial of BioMedica's treatment TroVax.
Another 350 patients have yet to be enrolled. The Trist (TroVax Renal Immunotherapy Survival Trial) study aims to show if Trovax can slow Tumour growth, and help patients to live longer, when combined with Chemotherapy.
Press Releases
Sanofi-Aventis Press (KC) 03-Jun-08
- Oxford BioMedica and Sanofi-Aventis report encouraging new TroVax® phase II trial results in renal cancer
Articles
Oxford Biomedica (KC) 20-Feb-08
- Oxford Biomedica Announces Data Safety Monitoring Board Recommendation to Continue TROVAX® Phase III Trist Study
Oxford Biomedica 20-Feb-08
- Oxford Biomedica Announces Data Safety Monitoring Board Recommendation to Continue TROVAX® Phase III Trist Study
|
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
